Amy Kruse

Dr. Amy Kruse is a General Partner of Prime Movers Lab where she leads their life sciences investments. As a neuroscientist and biologist, she discovers emerging new companies and leads in-depth due diligence into potential investments across areas including neuroscience, human augmentation, synthetic biology, longevity/regeneration, and agriculture. She also supports portfolio companies in evaluating and overcoming scientific and implementation challenges, with a specific emphasis on deploying complex technology into real-world environments. She serves on the boards of portfolio companies, Cognixion, Paradromics, Gilgamesh Pharmaceuticals, Attune Neurosciences and Iridia.

Amy brings 15+ years of experience to Prime Movers Lab, spanning a broad array of companies and positions. She is formerly the Chief Scientific Officer at Optios, an applied neuroscience company. She built the company’s scientific vision and completed acquisitions that resulted in a robust intellectual property portfolio. Amy also served as the Vice President and Chief Technology Officer at Cubic Global Defense overseeing innovation and the R&D portfolio across the entire defense enterprise. Early in her career, she served as a government civilian program manager at DARPA where she created and oversaw the Agency’s first performance-oriented neuroscience programs, with a combined budget of over $300M.

Amy is Founding Member of the Loomis Innovation Council and a Guest Lecturer for Singularity University. She earned a BS in Cell and Structural Biology and a PhD in Neuroscience from University of Illinois Champaign-Urbana, where she was awarded an NSF Graduate Fellowship.